Ikarian Capital, LLC Corbus Pharmaceuticals Holdings, Inc. Transaction History

Ikarian Capital, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.17 - $5.31 $79,111 - $2.47 Million	-465,359 Reduced 53.95%	397,168 $66,000
Q2 2022 Aug 12, 2022	SELL	$0.21 - $0.53 $28,371 - $71,603	-135,100 Reduced 13.54%	862,527 $217,000
Q1 2022 May 13, 2022	BUY	$0.32 - $0.67 $15,712 - $32,897	49,101 Added 5.18%	997,627 $530,000
Q3 2021 Nov 15, 2021	SELL	$1.01 - $1.82 $15,729 - $28,344	-15,574 Reduced 1.62%	948,526 $968,000
Q1 2021 May 17, 2021	BUY	$1.27 - $3.42 $1.05 Million - $2.82 Million	825,000 Added 593.1%	964,100 $1.9 Million
Q4 2020 Feb 12, 2021	BUY	$0.94 - $1.89 $130,753 - $262,899	139,100 New	139,100 $174,000

38.7K

Ticker CRBP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,268,000
Market Cap $2.08B
Description
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.